Rohit Gupta

💡Benchmarks in the investment industry serve as a standard for measuring the performance of securities, mutual funds, or investment managers. They provide a reference point for analyzing allocation, risk, and return of a portfolio, enabling investors to make informed decisions. Thanks Peter Walker for keeping us all informed!! Can’t wait for this!! Follow and get on the waitlist for this one! #benchmarks #fundraising #Capitalraise #founders #womenshealth #femhealth #medtech #wellness

16

#hiring If anyone knows an awesome engineer that would be interested in joining an emerging #AI company doing important work in #healthcare, please drop me a line! Andy AI is backed by General Catalyst, YCombinator, Greater Ventures, and others, and they’re looking to hire a full stack engineer (US based) who's excited about using AI to improve healthcare and reduce nurse burnout. Andy is AI software that automates clinical documentation for nurses who do home visits. A nurse makes an audio recording of the visit and Andy automatically generates a form that usually takes nurses 90 minutes to complete. Nurses love the product because it potentially saves them 15 hours of charting a week! The founders previously built healthcare AI at Google Health and Apple, and are now building their vision to transform home health. More about Andy AI: https://with-andy.com/ Nurses love it: https://lnkd.in/g9XqZrUq #GenAI #digitalhealth #hiring #engineers #healthtech

16

2 Comments

Having a Cars and Capital event tomorrow in Southern California with Oren Klaff. If you want to join message me. https://lnkd.in/gDQ4D39u Oren Klaff Bridger Pennington #InvestorEvent #FamilyOffice #InvestmentOpportunity #CarlsbadEvent #PrivateEquity #WealthManagement #InvestmentConference #CapitalRaising #NetworkingEvent #IndustryLeaders #FinancialGrowth #InvestorsMeetup #WealthBuilding #BusinessGrowth #InvestmentForum

24

1 Comment

The healthcare landscape is rapidly evolving, driven by advancements in technology and a deeper understanding of patient care. I had the pleasure of speaking with Ambar Bhattacharyya, Co-Managing Partner at Maverick Ventures, on the latest episode of The Full Ratchet. Ambar has partnered with numerous billion-dollar companies like hims & hers, Cityblock Health, Devoted Health, and ConcertAI. His unique journey from rural America to becoming a prominent figure in venture capital offers invaluable insights into the future of healthcare and technology. We discuss his investment strategy at Maverick Ventures, the megatrends shaping healthcare, the impact of AI on the industry, and the importance of integrated care. Ambar also shares his thoughts on the challenges and opportunities in healthcare investment, offering a comprehensive view of what lies ahead. Check out TFR Episode 438 to catch our conversation. You'll be glad you listened.

117

8 Comments

Shout out to Aaron Polack and the team at Lion Equity Partners for their 2024 Corporate Development report, which surveyed over 1,500 CorpDev professionals. The report highlights that 74% of the respondents reviewed less than 50 deals and only 21% rated their deal flow as high quality. Additionally, 31% did not close a transaction. These market conditions have led 25% of professionals to outsource some part of their deal origination. I expect this number to increase considerably with the proliferation of Buyside Brokers. The report also predicts a strong adoption boom for AI deal sourcing services. #corporatedevelopment #mergersacquisitions #privateequity #dealsourcing https://lnkd.in/eTvduYvF

42

1 Comment

🤔 Sounds like Pearl IO paid these guys...We didn't, but it doesn't hurt that they highlight how and why we exist and how we approach supporting PE partners succeed. Check out this recent Alvarez & Marsal webcast. Quick summary / takeaways: Generative AI is reshaping PE by accelerating deal execution, enhancing problem identification speed, and deepening analysis. Neat to see dialogue within PE continue regarding opportunities to enhance methods and outcomes. #PE #PrivateEquity #AI #Innovation #DataAnalytics #duediligence #diligence #portfoliomonitoring #valuecreation https://lnkd.in/dD3wznWS

4

Earlier this year, we surveyed our fellow Los Angeles-based GPs to get a pulse check on the LA venture ecosystem. Here’s what we found: 💗 Deal flow is healthy, and most LA venture investors (68%) are seeing the same or more deal flow YoY. ✈ LA investors are spending time in a variety of markets, with NYC, Austin, and SF following closely on LA’s heels. 🔍 Innovation is concentrated in AI and machine learning, space, and commerce. 💸 Funding is happening, but it’s barbell-shaped, with deals concentrated at the early and late stages. Funding post-Series A has been challenging. 🚩 LA is differentiated, but not without its challenges. Key difficulties include not attracting enough AI talent (despite having the largest number of engineers graduating from our region over any other in the United States); talent relocated to more tax-friendly or less expensive locations; and the great SoCal / NoCal divide 🙏 Thank you to all our many respondents! I’m so glad to be part of a venture ecosystem that includes great minds like Anna Barber, Brent Murri, W. Christine Choi, Sarah Tomolonius, Rob Smith, Win Chevapravatdumrong, John Tabis, Jill Royster, Jesse Draper, Ashley Balla, Britt Danneman, Tram Lai, Carmen Palafox, Elaine Russell, Deborah Benton Amanda Schutzbank, Brian Lee, Petra Griffith, Minnie Ingersoll, Shamin Walsh, Gabe Greenbaum...wow, this list could go on forever...plus too many other exceptional humans to name. You know who you are! Explore our findings more deeply with our survey dashboard: https://bit.ly/3JsaLaB

83

5 Comments

On this week's Andreessen Horowitz Raising Health podcast, Vijay Pande, PhD and I interviewed Tom Hale, CEO of ŌURA. Our conversation spans lots of fun topics, including: -- Our love for our Oura rings, despite them being literal “buzz kills” in revealing the ruinous effect of alcohol on sleep  -- How the worlds of consumer and healthcare are merging, as consumers essentially now have access to clinical-grade wearable devices  -- How AI algorithms are deployed in wearable devices & what wearables might look like 20 years from now (implanted into our bodies and clothes)  -- How the sexiest people sleep in earplugs and eye masks Check it out! https://lnkd.in/eTAsX_sY

83

9 Comments

We are excited to have announced our Series A lead investment in Abett. Founded by Mike Hanlon, the company provides a data layer that enables any self-insured employer in the US to receive a regular and consistent feed of their claims data so they can actually understand healthcare costs, the efficacy of their employee benefits, and how to better serve their employees (to whom they have a fiduciary responsibility). While this sounds like table stakes, it's far from the norm. After payroll, healthcare is the biggest cost consideration for American employers. A majority of Americans receive employer-based health insurance. A majority of those Americans receive insurance from a fully or partially self-funded plan (i.e., the employer is taking risk instead of the insurance company). Abett brings transparency and alignment to a thorny data problem to empower benefits leaders & CFOs. More to come on Acrew Capital's focus on the investing at the intersection of healthcare & data. cc: Mark Kraynak and Kwabena "KB" Nimo for their partnership on this investment.

120

4 Comments

This week Mikal Ventures brings you a 4-week breakdown of the non-US capital market with an emphasis on the Mikal verticals. Over the 4-week period ending May 29, a total of 1,545 new companies were added, with 101,688 companies included in the non-US Health Tech, Med Tech, Fin Tech, AI Tech, and Ed Tech verticals. The non-US AI Tech saw the greatest percentage growth in new companies for the period, weighing in at a notable 27%, nearly two times the overall vertical average of 15%. The non-US Heath Tech vertical led the group in transactions. Non-US Med Tech vertical lead in both SEC Filings and news articles. Mikal Ventures publishes these stats on a rolling 4-week basis to provide a perspective on how the verticals and new startups move through time. We hope you find them informative and thought-provoking. VC Investors are always adjusting their "Play Book" with a variety of options for investing. Mikal Ventures is one of those alternatives, offering curated solutions to real world problems. Reach out if you have questions on how we can be of assistance and bookmark https://mikalventures.com/ for additional insights and information.

4

This week Mikal Ventures brings you a 4-week breakdown of the US capital market with an emphasis on the Mikal verticals. Over the 4-week period ending June 10, just over 590 new companies were added, resulting in 95,661 companies included in the US Health Tech, Med Tech, Fin Tech, AI Tech, and Ed Tech verticals. AI Tech maintained its most active status, seeing the greatest percentage of growth in both new companies and transactions. The US Fin Tech vertical led the way in SEC Filings and news articles. Mikal Ventures publishes these stats to provide a perspective on how the verticals and new startups move through time. We hope you find them informative and thought-provoking. VC Investors are always adjusting their "Play Book" with a variety of options for investing. Mikal Ventures is one of those alternatives, offering curated solutions to real world problems. Reach out if you have questions on how we can be of assistance and bookmark https://mikalventures.com/ for additional insights and information.

4

Congratulations to CEO David McAnelly and the leadership team at Salt Creek Capital. Well done, David, and here's to continued success! Entrepreneurs looking for an exit? We are actively seeking opportunities to acquire businesses in the lower middle market in California. If you are considering selling your business, we would love to discuss potential opportunities and explore how we can achieve mutual success. Let's connect and see how we can collaborate and share a prosperous future. #Leadership #Growth #LosAngelesArea #MandA #ExitStrategy #Buinessforsale #BusinessBrokers #Innovation #BusinessDevelopment #StrategicAcquisition #IndustryLeader #MarketExpansion #Entrepreneurship #SellYourBusiness #BusinessOpportunity #FutureGrowth

9

3 Comments

Big congrats to our outstanding rising clinical research stars and global health practitioners at IGHS, UCSF! After months of dedicated hard work, we've all completed our qualifying oral exams. I believe these projects hold the potential to lead to the development of new healthcare technologies, services, or interventions that address pressing global health issues and aid underserved populations. The breadth of our research is evident in the diverse range of global health issues we explored, including but not limited to: 1. Women's empowerment and reintegration programs. 2. Telehealth systems for Native American children with complex medical needs. 3. Performance of COVID-19 exposure notification systems. 4. Mental health interventions during natural disasters in low- and middle-income countries. 5. Cancer screening and treatment access in underserved communities. 6. HIV care and support services. 7. Predictors of disease severity in pediatric febrile illnesses. 8. Cost-effectiveness analyses of various interventions (malaria detection, CAR T-cell therapy, cervical cancer screening). 9. Social media analysis of tobacco product marketing strategies. 10. Pediatric emergency triage tools for resource-limited settings. 11. The impact of food insecurity on mental health. 12. Acculturation, diet quality, and their connection to childhood obesity. 13. Nursing perspectives on COVID-19 pandemic interventions. This wide range of topics underscores the multifaceted nature of global health challenges and the critical need for innovative, interdisciplinary solutions. Furthermore, cost-effectiveness analyses, cost-of-illness studies, and implementation studies can inform strategies for sustainable and scalable solutions.

36

13 Comments

The world has never been more complex and dynamic. The cost of capital has increased, AI is in its infancy, data is abundant yet hard to navigate, and the world is still adjusting in a post-COVID era. With that, the role of the CFO has changed forever. CFOs must be more strategic, more disciplined and more forward-thinking. They must manage delicate relationships with the CEO, their teams and their board. At BCV, we’ve had a front row seat investing in the technology adopted by CFOs over the last 20 years. Now is the perfect time to create a CFO community where top-tier finance leaders can navigate these changes with their peers in a high-trust environment. We’ll use our depth of investing at BCV in the office of the CFO and financial technology plus the power of the broader Bain Capital network to keep advisory board members up to date on bleeding edge innovation to help them make informed decisions. We’ll look to advisory board members to help us understand their most pressing problems, as well as technology’s potential to solve them–including technology from our portfolio of companies. The CFO Advisory Board includes financial leaders from a variety of industries and geographies, representing late-stage growth companies to scaled public and private companies. I'm pleased to introduce the BCV CFO Advisory Board with Matt Harris, Noah Breslow, Alysaa Co, Nicole LoRusso, Joe DiMento, Sarah Hinkfuss, and Tina Dimitrova.

92

5 Comments

This is a good resource I've stumbled upon. It covers a plethora of VC and startup-related topics and contains links to expand your knowledge. https://lnkd.in/dqkdV4fA TL;DR: "It's the founders, stupid!" These two lines made me hover over: "I know the physical and emotional tolls that entrepreneurs face". "Resources for Managing Founder Anxiety and Depression" I've been one myself, and it's not for the faint-hearted. I struggled and failed many times. From the standpoint of a person working now for a VC fund, the ability to support a founder who was hit with too much at the same time, to know how to listen, mirror and label Chris Voss's style, and a bit of guidance to build confidence back can do wonders. Assisting portfolio companies doesn't have to be just intros and throwing money or unsolicited advice. And what about identifying troublesome founders before investing to prevent assisting portfolio companies from becoming a nightmare flop? Ahh, that's a tricky one. Startups fail for a variety of reasons. At the early stage, we should look at many things, to name a few: product-market fit, go-to-market, blue ocean or zero to one, CAC and LTV ratio, CAP table, passion, leadership potential, intelligence, technical ability, and many, many more. Crunch the numbers. Sure. What about the early stage? Limited information and knowledge when a decision has to be made, and the outcome is impossible to predict because the future is unknown and unknowable. Examine the founders. If you don't read the founders right and overlook some hidden toxic traits and coping mechanisms that mask something that can derail the startup and founders down the road (vulnerable narcissism, antisocial tendencies, Machiavellism, blameshifting or more benign like anxiety-prone, conflict avoidance, burn-out tendency, inability to delegate, perfectionism, risk aversion, etc.), the chances that it will be your next outlier significantly diminish. How many of you saw dead equity on the capable, founders' clash, low morale, a founder playing the sunk cost game with the fund after burning cash, lying, or even more brazen behaviours like experimenting with horse tranquilisers and smoking weed on a podcast? A "Sudden" shift of values with a splash of megalomania could lead to a CEO removal attempt by the board. Or stealing "HER" voice. It is fun to watch as a TV drama, not to deal with as your portfolio. We won't be able to see it all during a few conversations with the founders and not everyone is Wendy Rhoades from Billions. Knowing how to ask a question behind which is a hidden question and being able to detect when founders say what they think we want to hear to get the funding is a good start. Spending extra time learning that is a good investment. A splash of psychology, empathy, self-awareness, and emotional intelligence to become an excellent GP won't harm your ability to identify and help the right entrepreneurs build great companies.

14

This week Mikal Ventures brings you a 4-week breakdown of the US capital market with an emphasis on the Mikal verticals. Over the 4-week period ending April 15, just over 900 new companies were added, with 94,109 companies included in the US Health Tech, Med Tech, Fin Tech, AI Tech, and Ed Tech verticals. AI Tech again saw the greatest percentage of growth in new companies and transactions, weighing in at over double the vertical averages for the period. The US Fin Tech vertical again led the way in SEC Filings and news articles. Mikal Ventures publishes these stats on a rolling 4-week basis to provide a perspective on how the verticals and new startups move through time. We hope you find them informative and thought-provoking. VC Investors are always adjusting their "Play Book" with a variety of options for investing. Mikal Ventures is one of those alternatives, offering curated solutions to real world problems. Reach out if you have questions on how we can be of assistance and bookmark https://mikalventures.com/ for additional insights and information.

3

3 Comments

Still feeling energized from last week's roundtable on building successful relationships with hospitals. We invited 7 portfolio companies and health system leaders from Mayo Clinic, Cedars-Sinai and UCLA Health. The founders shared their questions ranging from the strategic to the nuts and bolts of closing partnerships. For example, how do you determine what measures of effectiveness help drive alignment? And how do you get all the stakeholders together to actually drive a decision. Answer: put them all in a room for half a day! “I think we're in a pivotal moment regarding how we assess AI. There are numerous risks currently dominating AI discussions, particularly those concerning bias and other associated risks. However, there's a notable absence of focus on evaluating the proactive value of AI. We need to consider what AI actually offers and what we want it to offer. It's not solely about determining whether it will cause harm; people are apprehensive about how this technology will be implemented. One perspective gaining traction involves ensuring the product's validation process is robust enough to prevent risks to various populations.” -Vladimir Manuel, Medical Director at UCLA Health From Vlad's comments above to perspectives others shared, we heard a sense of excitement for the promise of #AI and other new technologies. But we're also in a unique moment where the risks are not well understood. Still much to do here.

21